全文获取类型
收费全文 | 24764篇 |
免费 | 6910篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 408篇 |
儿科学 | 783篇 |
妇产科学 | 606篇 |
基础医学 | 1295篇 |
口腔科学 | 1593篇 |
临床医学 | 7227篇 |
内科学 | 5290篇 |
皮肤病学 | 632篇 |
神经病学 | 3141篇 |
特种医学 | 698篇 |
外国民族医学 | 3篇 |
外科学 | 3042篇 |
综合类 | 147篇 |
现状与发展 | 2篇 |
一般理论 | 13篇 |
预防医学 | 3640篇 |
眼科学 | 475篇 |
药学 | 826篇 |
中国医学 | 26篇 |
肿瘤学 | 1913篇 |
出版年
2024年 | 150篇 |
2023年 | 1345篇 |
2022年 | 398篇 |
2021年 | 908篇 |
2020年 | 1258篇 |
2019年 | 707篇 |
2018年 | 1700篇 |
2017年 | 1804篇 |
2016年 | 1774篇 |
2015年 | 1816篇 |
2014年 | 2161篇 |
2013年 | 2231篇 |
2012年 | 1232篇 |
2011年 | 1250篇 |
2010年 | 1336篇 |
2009年 | 1696篇 |
2008年 | 942篇 |
2007年 | 799篇 |
2006年 | 923篇 |
2005年 | 725篇 |
2004年 | 596篇 |
2003年 | 522篇 |
2002年 | 421篇 |
2001年 | 436篇 |
2000年 | 284篇 |
1999年 | 353篇 |
1998年 | 344篇 |
1997年 | 347篇 |
1996年 | 318篇 |
1995年 | 292篇 |
1994年 | 184篇 |
1993年 | 175篇 |
1992年 | 205篇 |
1991年 | 176篇 |
1990年 | 138篇 |
1989年 | 173篇 |
1988年 | 143篇 |
1987年 | 134篇 |
1986年 | 128篇 |
1985年 | 121篇 |
1984年 | 80篇 |
1983年 | 68篇 |
1982年 | 61篇 |
1980年 | 54篇 |
1979年 | 70篇 |
1978年 | 58篇 |
1977年 | 72篇 |
1976年 | 50篇 |
1972年 | 50篇 |
1970年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
991.
992.
993.
994.
Niki Katsiki MD Richard Ofori-Asenso MSc PhD Ele Ferrannini MD Mohsen Mazidi MSc 《Diabetes, obesity & metabolism》2020,22(6):1001-1005
The present meta-analysis evaluated the efficacy and safety of empagliflozin + linagliptin combination compared with either monotherapy [n=6 randomized controlled trials; 2857 adults with type 2 diabetes (T2DM) on diet + exercise ± metformin; 39.7% women; mean age: 54.6–59.9 years]. The combination of empagliflozin 10 mg + linagliptin 5 mg led to significantly greater reductions in glycated haemoglobin (HbA1c) compared with either drug alone over 24 weeks: weighted mean difference [WMD; −0.72%, 95% confidence interval (CI): −1.04, −0.40], and fasting plasma glucose (−1.60 mmol/L 95% CI: −2.21, −1.00). Similar results were observed when empagliflozin 25 mg + linagliptin 5 mg was compared with linagliptin 5 mg monotherapy or with empagliflozin 10 or 25 mg monotherapy. Patients with T2DM treated with the drug combination had more than three times higher likelihood of achieving HbA1c <7% than those on either monotherapy. Weight reduction was significantly greater in the combination group only when compared with linagliptin monotherapy. Safety profile was similar between combination treatment and monotherapies. Overall, the empagliflozin + linagliptin combination had superior efficacy and similar safety in achieving euglycaemia compared with either monotherapy. This combination, administered once daily, has the potential to reduce regimen complexity, enhance adherence and improve outcomes in clinical practice. 相似文献
995.
996.
Avivit Cahn MD Itamar Raz MD Marc Bonaca MD Ofri Mosenzon MD Sabina A. Murphy MPH Ilan Yanuv MSc Aliza Rozenberg MA John P. H. Wilding MD Deepak L. Bhatt MD Darren K. McGuire MD Ingrid A. M. Gause-Nilsson MD Martin Fredriksson MD Peter A. Johansson MSc Gyorgy Jermendy MD Samy Hadjadj MD Anna Maria Langkilde MD Marc S. Sabatine MD Stephen D. Wiviott MD Lawrence A. Leiter MD 《Diabetes, obesity & metabolism》2020,22(8):1357-1368
997.
998.
999.
1000.
Rebecca K. Vincent MSc David M. Williams MSc Marc Evans FRCP 《Diabetes, obesity & metabolism》2020,22(12):2227-2240
The increasing prevalence of diabetes and non-alcoholic fatty liver disease (NAFLD) is a growing public health concern associated with significant morbidity, mortality and economic cost, particularly in those who progress to cirrhosis. Medical treatment is frequently limited, with no specific licensed treatments currently available for people with NAFLD. Its association with diabetes raises the possibility of shared mechanisms of disease progression and treatment. With the ever-growing interest in the non-glycaemic effects of diabetes medications, studies and clinical trials have investigated hepatic outcomes associated with the use of drug classes used for people with type 2 diabetes (T2D), such as glucagon-like peptide-1 (GLP-1) analogues or sodium-glucose co-transporter-2 (SGLT2) inhibitors. Studies exploring the use of GLP-1 analogues or SGLT2 inhibitors in people with NAFLD have observed improved measures of hepatic inflammation, liver enzymes and radiological features over short periods. However, these studies tend to have variable study populations and inconsistent reported outcomes, limiting comparison between drugs and drug classes. As these drugs appear to improve biomarkers of NAFLD, clinicians should consider their use in patients with NAFLD and T2D. However, further evidence with greater participant numbers and longer trial durations is required to support specific licensing for people with NAFLD. Larger trials would allow reporting of major adverse hepatic events, akin to cardiovascular and renal outcome trials, to be determined. This would provide a more meaningful evaluation of the impact of these drugs in NAFLD. Nevertheless, these drugs represent a future potential therapeutic avenue in this difficult-to-treat population and may beget significant health and economic impacts. 相似文献